OBJECT: The role of genetic polymorphisms in the neurological outcome of patients after carotid endarterectomy (CEA) remains unclear. There are single nucleotide polymorphisms (SNPs) that predispose patients to postoperative cognitive dysfunction (CD). We aim to assess the predictability of three complement cascade-related SNPs for CD in patients having CEAs. METHODS: In 252 patients undergoing CEA, genotyping was performed for the following polymorphisms: complement component 5 (C5) rs17611, mannose-binding lectin 2 (MBL2) rs7096206, and complement factor H (CFH) rs1061170. Differences among genotypes were analyzed via the chi-square test. Patients were evaluated with a neuropsychometric battery for CD 1 day and 1 month after CEA. A multiple logistic regression model was created. All variables with univariate p < 0.20 were included in the final model. RESULTS: The C5 genotypes A/G (OR 0.26, 95% CI 0.11-0.60, p = 0.002) and G/G (OR 0.22, 95% CI 0.09-0.52, p < 0.001) were significantly associated with lower odds of exhibiting CD at 1 day after CEA compared with A/A. The CFH genotypes C/T (OR 3.37, 95% CI 1.69-6.92, p < 0.001) and C/C (OR 3.67, 95% CI 1.30-10.06, p = 0.012) were significantly associated with higher odds of exhibiting CD at 1 day after CEA compared with T/T. Statin use was also significantly associated with lower odds of exhibiting CD at 1 day after CEA (OR 0.43, 95% CI 0.22-0.84, p = 0.01). No SNPs were significantly associated with CD at 1 month after CEA. CONCLUSIONS: The presence of a deleterious allele in the C5 and CFH SNPs may predispose patients to exhibit CD after CEA. This finding supports previous data demonstrating that the complement cascade system may play an important role in the development of CD. These findings warrant further investigation.
OBJECT: The role of genetic polymorphisms in the neurological outcome of patients after carotid endarterectomy (CEA) remains unclear. There are single nucleotide polymorphisms (SNPs) that predispose patients to postoperative cognitive dysfunction (CD). We aim to assess the predictability of three complement cascade-related SNPs for CD in patients having CEAs. METHODS: In 252 patients undergoing CEA, genotyping was performed for the following polymorphisms: complement component 5 (C5) rs17611, mannose-binding lectin 2 (MBL2) rs7096206, and complement factor H (CFH) rs1061170. Differences among genotypes were analyzed via the chi-square test. Patients were evaluated with a neuropsychometric battery for CD 1 day and 1 month after CEA. A multiple logistic regression model was created. All variables with univariate p < 0.20 were included in the final model. RESULTS: The C5 genotypes A/G (OR 0.26, 95% CI 0.11-0.60, p = 0.002) and G/G (OR 0.22, 95% CI 0.09-0.52, p < 0.001) were significantly associated with lower odds of exhibiting CD at 1 day after CEA compared with A/A. The CFH genotypes C/T (OR 3.37, 95% CI 1.69-6.92, p < 0.001) and C/C (OR 3.67, 95% CI 1.30-10.06, p = 0.012) were significantly associated with higher odds of exhibiting CD at 1 day after CEA compared with T/T. Statin use was also significantly associated with lower odds of exhibiting CD at 1 day after CEA (OR 0.43, 95% CI 0.22-0.84, p = 0.01). No SNPs were significantly associated with CD at 1 month after CEA. CONCLUSIONS: The presence of a deleterious allele in the C5 and CFH SNPs may predispose patients to exhibit CD after CEA. This finding supports previous data demonstrating that the complement cascade system may play an important role in the development of CD. These findings warrant further investigation.
Authors: Diederik Van Dijk; Erik W L Jansen; Ron Hijman; Arno P Nierich; Jan C Diephuis; Karel G M Moons; Jaap R Lahpor; Cornelius Borst; Annemieke M A Keizer; Hendrik M Nathoe; Diederick E Grobbee; Peter P T De Jaegere; Cor J Kalkman Journal: JAMA Date: 2002-03-20 Impact factor: 56.272
Authors: E S Connolly; C J Winfree; A Rampersad; R Sharma; W J Mack; J Mocco; R A Solomon; G Todd; D O Quest; Y Stern; E J Heyer Journal: Neurosurgery Date: 2001-11 Impact factor: 4.654
Authors: J T Moller; P Cluitmans; L S Rasmussen; P Houx; H Rasmussen; J Canet; P Rabbitt; J Jolles; K Larsen; C D Hanning; O Langeron; T Johnson; P M Lauven; P A Kristensen; A Biedler; H van Beem; O Fraidakis; J H Silverstein; J E Beneken; J S Gravenstein Journal: Lancet Date: 1998-03-21 Impact factor: 79.321
Authors: E J Heyer; D C Adams; R A Solomon; G J Todd; D O Quest; D J McMahon; S D Steneck; T F Choudhri; E S Connolly Journal: Stroke Date: 1998-06 Impact factor: 7.914
Authors: Eric J Heyer; Joanna L Mergeche; Samuel S Bruce; Justin T Ward; Yaakov Stern; Zirka H Anastasian; Donald O Quest; Robert A Solomon; George J Todd; Alan I Benvenisty; James F McKinsey; Roman Nowygrod; Nicholas J Morrissey; E Sander Connolly Journal: Stroke Date: 2013-02-12 Impact factor: 7.914
Authors: Eric J Heyer; Joanna L Mergeche; Zirka H Anastasian; Minjae Kim; Kaitlin A Mallon; E Sander Connolly Journal: Neurosurgery Date: 2014-03 Impact factor: 4.654
Authors: Alison R Clarke; Brandon R Christophe; Anadjeet Khahera; Justin L Sim; E Sander Connolly Journal: Front Immunol Date: 2019-07-30 Impact factor: 7.561